Biocon (BSE: 532523), an Indian drugmaker that together with Netherlands-headquartered Mylan (Nasdaq: MYL) is a frontrunner in the race to take big-selling biosimilars to major markets, has suffered a damaging blow affecting two of its oncology submissions in Europe.
Following Wednesday’s trading, Biocon’s share price was 6% down at 328.25 Indian rupees ($5.11), with markets taking a dim view of news that it has had to withdraw the applications to the European Medicines Agency (EMA).
These were for biosimilars referencing Herceptin (trastuzumab), a big-seller from Swiss pharma major Roche (ROG: SIX) for certain HER2-positive breast and gastric cancers, and Neulasta (pegfilgrastim), a drug from US biotech Amgen (Nasdaq: AMGN) for low white blood cell counts in patients undergoing chemotherapy for cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze